Systematic review indicates no difference in reoperations between 1-level and 2-level cervical disc arthroplasty, suggesting future research is necessary.
Study Design. Systematic review with network meta-analysis (NMA). Objective. To determine if there is a difference in adjacent segment disease (ASD) and all-cause reoperations between 1-level and contiguous 2-level cervical disc arthroplasty (CDA1, CDA2). Summary of Background Data. There are conflicting results from previous studies that there is a difference in reoperations between CDA1 and CDA2 possibly reflecting undertreatment of adjacent cervical degenerative disc disease with its natural history in CDA1. Methods. We conducted a random-effects NMA with only FDA Investigational Device Exemption (IDE) studies and international randomized controlled trials (RCTs) with more than 5 years of follow-up. Direct comparisons included CDA1 versus 1-level anterior cervical discectomy with fusion (ACDF1), CDA2 versus 2-level ACDF (ACDF2), and ACDF2 versus ACDF1; together, these formed a connected network in which ACDF served as the anchoring comparator, enabling anchored indirect comparisons between CDA1 and CDA2. Binary outcomes (ASD and all-cause reoperations) were analyzed using odds ratios within a frequentist framework in Stata. Results. NMA for ASD reoperations had 13 studies directly comparing CDA1 vs ACDF1 (n=4,135), 2 studies comparing 2-level CDA2 vs ACDF2 (n=789), and 1 study comparing ACDF2 vs ACDF1 (n=207). Results demonstrated no significant difference in ASD reoperation (OR 0.98, 95% CI 0.38–2.54) for CDA1 versus CDA2. For all-cause reoperations there were 14 studies directly comparing CDA1 vs ACDF1 (n=4,246), 2 studies comparing CDA2 vs ACDF2 (n=837), and 1 study comparing ACDF2 vs ACDF1 (n=223). CDA1 versus CDA2, demonstrated no significant difference in all-cause reoperation (OR 0.98, 95% CI 0.40–2.39). Conclusions. In our comprehensive NMA of selected FDA IDE studies and international RCTs with long-term follow-up, we found no significant difference between 1-level CDA and 2-level CDA with respect to ASD and all-cause reoperations. Future research is needed to see if our results are replicated in real world data.
No takes yet. Share an insight, caveat, or question.
Guppy et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: